Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 3619-3627

  Maae, Else ^a,c   Andersen, Rikke Fredslund ^b   Steffensen, Karina Dahl ^a,c   Jakobsen, Erik Hugger ^a   Brandslund, Ivan ^b,c   Sørensen, Flemming Brandt ^b,c   Jakobsen, Anders ^a,c  

^a LILLEBAELT HOSPITAL   (Denmark)

^b Department of Clinical Biochemistry ^*  (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

+936C>T; 1154G>A; 1498T>C; 2578C>A; 634G>C; 7C>T; Breast cancer; HER2; Single nucleotide polymorphism; VEGFA

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; VASCULOTROPIN;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER PROGNOSIS; CARCINOGENESIS; CONTROLLED STUDY; DNA ISOLATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; GERM-LINE MUTATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTOR, ERBB-2; TAXOIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867028191     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
2. Minchenko A, Bauer T, Salceda S and Caro J: Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest 71: 374-379, 1994. (Pubitemid 24310017)
3. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003. (Pubitemid 36749215)
4. Ferrara N: The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS pp. 209-231, 2005.
5. Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027, 2005. (Pubitemid 46202320)
6. Kut C, Mac GF and Popel AS: Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 97: 978-985, 2007. (Pubitemid 47519292)
7. Gasparini G: Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 5(Suppl 1): 37-44, 2000.
8. Lord S and Harris AL: Angiogenesis -Still a worthwhile target for breast cancer therapy? Breast Cancer Res 12(Suppl 4): S19, 2010.
9. Maae E, Nielsen M, Steffensen KD, Jakobsen EH, Jakobsen A and Sorensen FB: Estimation of immunohistochemical expression of VEGF in ductal carcinomas of the breast. J Histochem Cytochem 59: 750-760, 2011.
10. Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, Venitz J and Figg WD: The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 8: 2496-2508, 2009.
11. Minchenko A, Salceda S, Bauer T and Caro J: Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res 40: 35-39, 1994. (Pubitemid 24292725)
12. Watson CJ, Webb NJ, Bottomley MJ and Brenchley PE: Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12: 1232-1235, 2000. (Pubitemid 30611801)
13. Schneider BP, Radovich M, Sledge GW, Robarge JD, Li L, Storniolo AM, Lemler S, Nguyen AT, Hancock BA, Stout M, Skaar T and Flockhart DA: Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 111: 157-163, 2008. (Pubitemid 352009224)
14. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Haas J and Samonigg H: A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 106: 468-471, 2003. (Pubitemid 36966201)
15. Kataoka N, Cai Q, Wen W, Shu XO, Jin F, Gao YT and Zheng W: Population-based casecontrol study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev 15: 1148-1152, 2006.
16. Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R, Henriksson R, Chen B, Pamula J, Pekala W, Zientek H, Rogozinska-Szczepka J, Utracka-Hutka B, Hallmans G and Forsti A: Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 11: 3647-3653, 2005. (Pubitemid 40685580)
17. Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez C, Stevens VL, Patel AV, Thun MJ and Calle EE: Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res 8: R22, 2006.
18. Krippl P, Langsenlehner U, Samonigg H, Renner W and Koppel H: Vascular endothelial growth factor in predicting outcome in breast cancer. Clin Cancer Res 10: 8752-8753, 2004. (Pubitemid 40053446)
19. Lu H, Shu XO, Cui Y, Kataoka N, Wen W, Cai Q, Ruan ZX, Gao YT and Zheng W: Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 65: 5015-5019, 2005. (Pubitemid 40827307)
20. Balasubramanian SP, Cox A, Cross SS, Higham SE, Brown NJ and Reed MW: Influence of VEGFA gene variation and protein levels in breast cancer susceptibility and severity. Int J Cancer 121: 1009-1016, 2007. (Pubitemid 47101636)
21. Kidd LR, Brock GN, Vancleave TT, Benford ML, Lavender NA, Kruer TL and Wittliff JL: Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival. Cancer Causes Control 21: 1545-1557, 2010.
22. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B and Pilger E: A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37: 443-448, 2000. (Pubitemid 32037619)
23. Steffensen KD, Waldstrom M, Brandslund I and Jakobsen A: The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol 117: 109-116, 2010.
24. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235: 177-182, 1987. (Pubitemid 17231334)
25. Ellis LM: Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am 18: 1007-1021, viii, 2004.
26. Tortora G, Ciardiello F and Gasparini G: Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol 5: 521-530, 2008.
27. Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, Yang W, Yin G, Hittelman WN and Yu D: ERBB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res 66: 2028-2037, 2006.
28. Laughner E, Taghavi P, Chiles K, Mahon PC and Semenza GL: HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF- 1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995-4004, 2001. (Pubitemid 32476461)
29. Blackwell KL, Dewhirst MW, Liotcheva V, Snyder S, Broadwater G, Bentley R, Lal A, Riggins G, Anderson S, Vredenburgh J, Proia A and Harris LN: HER2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clin Cancer Res 10: 4083-4088, 2004. (Pubitemid 38812486)
30. Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ and Pegram MD: Association between HER2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10: 1706-1716, 2004. (Pubitemid 38435562)
31. Loureiro RM, Maharaj AS, Dankort D, Muller WJ and D'Amore PA: ERBB2 overexpression in mammary cells up-regulates VEGF through the core promoter. Biochem Biophys Res Commun 326: 455-465, 2005. (Pubitemid 39593568)
32. Fattaneh A. Tavassoli, Peter Devilee (eds.). World Health Organization Classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon, IARC Press, 2003.
33. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 41: 151-152, 2002.
34. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS and Greene FL: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20: 3628-3636, 2002. (Pubitemid 34983222)
35. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van d, V, Wheeler TM and Hayes DF: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131: 18-43, 2007. (Pubitemid 46174133)
36. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S and Miller KD: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26: 4672-4678, 2008.
37. Langsenlehner U, Wolf G, Langsenlehner T, Gerger A, Hofmann G, Clar H, Wascher TC, Paulweber B, Samonigg H, Krippl P and Renner W: Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian "tumor of breast tissue: incidence, genetics, and environmental risk factors" study. Breast Cancer Res Treat 109: 297-304, 2008. (Pubitemid 351644853)
38. Rozen S and Skaletsky H: Primer3 on the WWW for general users and for biologist programmers. In: Bioinformatics Methods and Protocols: Methods in Molecular Biology. Krawetz S, Misener S (eds.). Totowa, Humana Press, pp. 365-386, 2000.
39. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD and Zujewski JA: Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25: 2127-2132, 2007. (Pubitemid 46972801)
40. Stephens M, Smith NJ and Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68: 978-989, 2001. (Pubitemid 32289743)
41. Stephens M and Donnelly P: A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73: 1162-1169, 2003. (Pubitemid 37414228)
42. Schneider BP, Skaar TC, Sledge GW, Badve S, Li L and Flockhart DA: Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. Breast Cancer Res Treat 96: 209-215, 2006.
43. Taneja P, Maglic D, Kai F, Zhu S, Kendig RD, Fry EA and Inoue K: Classical and novel prognostic markers for breast cancer and their clinical significance. Clin Med Insights Oncol 4: 15-34, 2010.
44. Normanno N, Morabito A, De LA, Piccirillo MC, Gallo M, Maiello MR and Perrone F: Target-based therapies in breast cancer: Current status and future perspectives. Endocr Relat Cancer 16: 675-702, 2009.
45. Izumi Y, Xu L, di TE, Fukumura D and Jain RK: Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 416: 279-280, 2002.